The Journal of Urology
Volume 183, Issue 3 , Pages 958-962 , March 2010

Stage pT0 After Radical Prostatectomy With Previous Positive Biopsy Sets: A Multicenter Study

  • Thomas Bessède

      Affiliations

    • Centre Hospitalier Universitaire Henri Mondor, Créteil, France
    • ,
  • Michel Soulié

      Affiliations

    • Centre Hospitalier Universitaire Rangueil, Toulouse, France
    • ,
  • Nicolas Mottet

      Affiliations

    • Clinique Mutualiste Saint-Etienne, Saint-Etienne, France
    • ,
  • Xavier Rebillard

      Affiliations

    • Clinique Beausoleil, Montpellier, France
    • ,
  • Michaël Peyromaure

      Affiliations

    • Centre Hospitalier Universitaire Cochin, Paris, France
    • ,
  • Vincent Ravery

      Affiliations

    • Centre Hospitalier Universitaire Bichat, Paris, France
    • ,
  • Laurent Salomon

      Affiliations

    • Centre Hospitalier Universitaire Henri Mondor, Créteil, France
    • Corresponding Author InformationCorrespondence: Department of Urology, Hospital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France (telephone: 33 + (0) 1 49 81 25 53; FAX: 33 + (0) 1 49 81 25 64)
    • ,
  • Cancerology Committee of the French Urological Association

Received 18 June 2009

References 

  1. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Manual for Staging Cancer. In: 6th ed.. New York: Springer; 2002;p. 337
  2. Kollermann J, Feek U, Muller H, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 2000;38:714
  3. Herkommer K, Kuefer R, Gschwend JE, et al. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004;45:36
  4. Goldstein NS, Begin LR, Grody WW, et al. Minimal or no cancer in radical prostatectomy specimens (Report of 13 cases of the “vanishing cancer phenomenon.”). Am J Surg Pathol. 1995;19:1002
  5. Mazzucchelli R, Barbisan F, Tagliabracci A, et al. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch. 2007;450:371
  6. Postma R, de Vries SH, Roobol MJ, et al. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer. 2005;103:708
  7. MJ Stamey TA, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutives radical prostatectomies. J Urol. 1988;139:1235
  8. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68
  9. Corica FA, Bostwick DG. Clinically unsuspected and undetected (clinical stage t0) prostate cancer diagnosed on random needle biopsy. Urology. 1999;53:557
  10. Schulman CC, Sassine AM. Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol. 1993;24:450
  11. Noguchi M, Noda S, Nakashima O, et al. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. Oncol Rep. 2002;9:1075
  12. Kollermann J, Hopfenmuller W, Caprano J, et al. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis. Eur Urol. 2004;45:42
  13. Prayer-Galetti T, Gardiman M, Sacco E, et al. Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer. Anal Quant Cytol Histol. 2007;29:79
  14. Bostwick DG, Bostwick KC. ‘Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004;94:57
  15. Duffield AS, Epstein JI. Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides. Am J Surg Pathol. 2009;33:120
  16. Descazeaud A, Zerbib M, Flam T, et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy?. Eur Urol. 2006;50:1248
  17. Kommu S. A model to explain the ‘vanishing' prostate—the curative biopsy theory. BJU Int. 2004;94:939
  18. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol. 1997;21:174
  19. Suba E, Pfeiffer J, Raab S. Patient identification error among prostate needle core biopsy specimens: are we ready for a DNA time-out?. J Urol. 2007;178:1245
  20. Cao D, Hafez M, Berg K, et al. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen? (A microsatellite analysis of specimen identity). Am J Surg Pathol. 2005;29:467
  21. Trpkov K, Yuan G, Hay R, et al. No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings and DNA specimen identity analysis. Arch Pathol Lab Med. 2006;130:811
  22. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368
  23. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  24. Thwaini A, Anjum F, Kalubac J, et al. ‘Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004;94:1145

PII: S0022-5347(09)02905-X

doi: 10.1016/j.juro.2009.11.016

The Journal of Urology
Volume 183, Issue 3 , Pages 958-962 , March 2010

Article Tools